Last updated: September 4, 2026
Nilotinib d-tartrate does not have an identifiable FDA-approved brand, standalone Orange Book listing, or publicly reported commercial revenue base. The approved nilotinib product is Tasigna, which contains nilotinib hydrochloride monohydrate and is marketed by Novartis for Philadelphia chromosome-positive chronic myeloid leukemia, or Ph+ CML.[1] Financial analysis for nilotinib d-tartrate therefore depends on whether it is being evaluated as an alternative pharmaceutical salt, an API form, or a development-stage product.
What is nilotinib d-tartrate?
Nilotinib d-tartrate is a salt form of nilotinib. It is distinct from the nilotinib hydrochloride monohydrate used in Tasigna. A different salt can affect crystallinity, solubility, hygroscopicity, stability, manufacturability, and intellectual-property positioning, but it does not automatically create a separate approved drug market.
| Attribute |
Nilotinib d-tartrate |
Tasigna |
| Active pharmaceutical ingredient |
Nilotinib |
Nilotinib |
| Salt form |
D-tartrate |
Hydrochloride monohydrate |
| FDA-approved product identified |
No |
Yes |
| Approved brand |
None identified |
Tasigna |
| Manufacturer |
No commercial sponsor identified |
Novartis |
| FDA indication |
None identified |
Ph+ CML |
| Orange Book product |
None identified |
Yes, for approved nilotinib product listings |
| Biosimilar framework |
Not applicable |
Not applicable |
| Standalone revenue disclosure |
None identified |
Reported within Novartis oncology portfolio |
The distinction matters commercially. A manufacturer cannot generally rely on Tasigna’s approval to market nilotinib d-tartrate as an interchangeable product. A new salt may require an abbreviated or full regulatory pathway depending on the product’s pharmaceutical equivalence, bioequivalence, formulation, labeling, and regulatory jurisdiction.
Is nilotinib d-tartrate an FDA-approved drug?
No FDA-approved product marketed specifically as nilotinib d-tartrate has been identified. FDA approved Tasigna on October 29, 2007, for adults with newly diagnosed Ph+ CML in the chronic phase and for certain patients with Ph+ CML in chronic or accelerated phase who were resistant or intolerant to prior therapy.[1]
The approved Tasigna label identifies nilotinib hydrochloride monohydrate as the drug substance. The labeled dosage forms are hard gelatin capsules containing 50 mg, 150 mg, or 200 mg of nilotinib, depending on the product presentation and market version.[1]
What is the FDA regulatory status of Tasigna?
Tasigna is an approved small-molecule oncology drug. Its regulatory history includes:
| FDA milestone |
Date or status |
| Initial approval |
October 29, 2007 |
| Initial disease area |
Ph+ CML |
| Regulatory pathway |
New drug application |
| Drug class |
BCR-ABL tyrosine kinase inhibitor |
| Active moiety |
Nilotinib |
| Approved salt |
Nilotinib hydrochloride monohydrate |
| Pediatric labeling |
Added through subsequent regulatory actions |
| Current status |
Approved product, subject to generic competition |
Nilotinib d-tartrate would require its own regulatory assessment. The relevant issue would be whether FDA considers the salt change sufficiently equivalent to support an abbreviated application or whether additional clinical, pharmacokinetic, or pharmaceutical-development data are required.
What patents protect nilotinib d-tartrate?
No publicly identifiable, commercially relevant patent estate has been established for nilotinib d-tartrate as an approved product. Protection could still exist through patents covering the salt, crystalline form, polymorph, formulation, manufacturing process, or therapeutic use.
Potential patent categories include:
- Salt and solid-state patents. These may claim nilotinib d-tartrate, specific stoichiometric ratios, hydrates, solvates, polymorphs, or crystallization conditions.
- Formulation patents. Claims may cover capsule composition, particle size, dissolution performance, excipients, or methods for improving oral exposure.
- Method-of-use patents. Claims may cover treatment of CML, dosing schedules, treatment-free remission strategies, or use in patients with specific BCR-ABL mutation profiles.
- Manufacturing patents. Claims may cover intermediates, chiral resolution, salt formation, purification, or control of impurities.
- Combination patents. Claims may cover nilotinib with other antineoplastic agents or treatment sequences.
A patent application or granted patent covering d-tartrate would not establish a commercial market. The commercial value would depend on claim scope, enforceability, remaining patent term, regulatory approval, and freedom to operate against Novartis’ nilotinib patents and regulatory exclusivities.
How strong is the patent estate for nilotinib d-tartrate?
On the available market evidence, the d-tartrate estate is commercially unvalidated. There is no identified approved product, publicly reported sales base, or disclosed license transaction specifically tied to nilotinib d-tartrate.
The estate would be stronger if it has:
- Claims directed specifically to the d-tartrate salt rather than broad nilotinib chemistry.
- A distinct crystalline form with superior stability or manufacturability.
- Demonstrated pharmaceutical advantages over nilotinib hydrochloride monohydrate.
- Patent term extending beyond expected regulatory review and launch.
- Data supporting bioequivalence or clinical utility.
- Manufacturing claims that are difficult to design around.
The estate would be weaker if the d-tartrate is only one of many obvious pharmaceutically acceptable salts, lacks comparative performance data, or can be avoided through use of nilotinib free base or another salt.
When does nilotinib lose exclusivity?
Nilotinib d-tartrate has no established exclusivity-loss date because no approved product has been identified. Tasigna’s market exclusivity is different from patent protection and must be analyzed separately.
| Exclusivity category |
Nilotinib d-tartrate |
Tasigna |
| New chemical entity exclusivity |
None identified |
Historical exclusivity associated with initial approval |
| Orphan exclusivity |
None identified for d-tartrate |
Potentially relevant only to qualifying indications |
| Patent exclusivity |
No validated d-tartrate position identified |
Historical and product-specific patents |
| Generic competition |
No approved d-tartrate generic identified |
Generic nilotinib competition has emerged |
| Biosimilar exclusivity |
Not applicable |
Not applicable |
The initial Tasigna approval occurred in 2007. The practical loss of exclusivity has been driven by the expiration or invalidation of relevant patents and the approval of generic nilotinib products, rather than by a single universal date.[1][2]
What is the Orange Book status of nilotinib d-tartrate?
Nilotinib d-tartrate has no identified Orange Book-listed product. FDA’s Orange Book lists approved drug products and relevant patent and exclusivity information associated with those products. An unapproved salt form will not have an independent Orange Book position unless a product containing that form is approved.
Tasigna and approved generic nilotinib products may appear in FDA’s approved drug databases under the relevant nilotinib product and dosage form. Orange Book status should not be interpreted as proof that every nilotinib salt is substitutable. Pharmaceutical equivalence depends on the active ingredient, dosage form, strength, route, and applicable FDA determinations.[2]
Which companies are challenging Tasigna exclusivity?
Generic competition has focused on nilotinib products corresponding to the approved Tasigna product, not on a publicly established nilotinib d-tartrate product.
Potential competitive categories include:
- Generic capsule manufacturers filing abbreviated new drug applications.
- Companies challenging listed patents through Paragraph IV certifications.
- Contract manufacturers developing alternative nilotinib salt or solid-state forms.
- Oncology companies evaluating nilotinib for geographic or indication-specific opportunities.
The exact commercial impact depends on the ANDA applicant, patent certification, litigation outcome, settlement terms, and launch restrictions. Public regulatory records should be reviewed for each applicant because a Paragraph IV filing is not equivalent to a launched product.
What Paragraph IV risks exist for nilotinib d-tartrate?
A nilotinib d-tartrate applicant could face several forms of challenge:
- Composition-of-matter claims. These may apply if the patent language covers nilotinib broadly or includes the d-tartrate salt.
- Solid-form claims. A d-tartrate crystal or polymorph could be challenged as anticipated, obvious, or insufficiently enabled.
- Formulation claims. A product could face infringement allegations based on capsule composition or dissolution characteristics.
- Use claims. A label directed to patented CML treatment methods could create induced-infringement exposure.
- Regulatory filing disputes. FDA may determine that the proposed product does not qualify for an abbreviated pathway if the salt change affects pharmaceutical equivalence.
The key litigation question is whether the applicant can launch with a noninfringing label and a formulation that avoids listed claims. That analysis cannot be inferred from the existence of the d-tartrate salt alone.
What formulations are protected by nilotinib patents?
The approved commercial formulation is an oral capsule. The principal formulation issues are nilotinib’s limited and variable absorption, food effects, dose administration requirements, particle properties, and capsule performance.[1]
A d-tartrate formulation could create commercial value if it delivers one or more of the following:
- Lower variability in exposure.
- Reduced food-effect restrictions.
- Improved dissolution.
- Lower capsule burden.
- Better chemical or physical stability.
- Simplified manufacturing.
- More consistent absorption in patients with gastrointestinal impairment.
These advantages would need to be supported by comparative pharmaceutical and clinical data. A salt change without a measurable performance benefit would have limited differentiation from generic nilotinib hydrochloride monohydrate.
What is the market size and revenue trajectory for nilotinib d-tartrate?
No standalone revenue has been publicly reported for nilotinib d-tartrate. Its current identifiable market value is therefore zero as a marketed pharmaceutical product, while its development value is contingent on regulatory approval, patent protection, and differentiation.
Tasigna revenue provides a proxy for the underlying nilotinib market, but it should not be attributed to the d-tartrate form. Novartis has reported Tasigna within its oncology portfolio and has disclosed declining pressure from generic competition in its financial reporting.[3]
| Financial metric |
Nilotinib d-tartrate |
Tasigna |
| Standalone sales |
None identified |
Reported historically by Novartis |
| Revenue growth |
Not measurable |
Declining after generic entry and maturity |
| Price environment |
No established price |
Pressure from generic substitution |
| Commercial maturity |
Development-stage or uncommercialized |
Mature branded product |
| Reimbursement evidence |
None identified |
Established oncology reimbursement |
| Investor relevance |
Option value only |
Erosion and portfolio-management issue |
What drives the financial trajectory?
The principal value drivers are:
- Approval as a differentiated nilotinib product.
- Demonstrated superiority in absorption, dosing convenience, or tolerability.
- Remaining patent term.
- Ability to obtain regulatory exclusivity.
- Geographic licensing rights.
- Manufacturing cost relative to generic nilotinib.
- Access to CML treatment markets where generic substitution is limited.
- Use in treatment-free remission or earlier-line therapy, subject to approved labeling and clinical evidence.
The commercial ceiling is constrained by the maturity of the CML market. Nilotinib competes with imatinib, dasatinib, bosutinib, ponatinib, asciminib, and generic versions of older tyrosine kinase inhibitors. A new salt would need more than chemical novelty to command a premium.
How does nilotinib d-tartrate compare with competing CML drugs?
| Product |
Mechanism |
Commercial position |
Relevance to d-tartrate |
| Tasigna |
BCR-ABL inhibitor |
Mature branded nilotinib product with generic pressure |
Direct reference product |
| Generic nilotinib |
BCR-ABL inhibitor |
Lower-price substitute for approved nilotinib |
Primary price competitor |
| Imatinib |
BCR-ABL inhibitor |
Established, largely generic |
Major low-cost alternative |
| Dasatinib |
BCR-ABL inhibitor |
Established TKI with generic competition |
Competes in first-line and later-line settings |
| Bosutinib |
BCR-ABL inhibitor |
Differentiated tolerability and sequencing profile |
Alternative TKI |
| Ponatinib |
BCR-ABL inhibitor |
Used in resistant disease and mutation-specific settings |
Higher-risk, specialized competitor |
| Asciminib |
STAMP inhibitor |
Newer targeted therapy with differentiated mechanism |
Stronger innovation benchmark |
A d-tartrate product would compete against low-cost generic nilotinib on price and against asciminib and other TKIs on clinical differentiation. Without improved clinical utility, the salt is unlikely to support premium pricing.
What licensing deals involve nilotinib d-tartrate?
No publicly disclosed licensing transaction specifically involving nilotinib d-tartrate has been identified. Novartis retains the principal commercial association with nilotinib through Tasigna, while generic manufacturers may obtain rights to market nilotinib products through patent settlements, supply arrangements, or independent regulatory filings.
A d-tartrate licensing transaction would likely be structured around one of four assets:
- Regional development and commercialization rights.
- A salt or polymorph patent portfolio.
- Manufacturing technology and know-how.
- A regulatory package supporting an abbreviated or hybrid application.
The absence of a disclosed transaction limits valuation. The asset should be valued as a development and IP option, not as a revenue-generating pharmaceutical franchise.
What generic launch scenarios exist for nilotinib d-tartrate?
Three launch scenarios are commercially plausible:
- No launch. The salt fails to demonstrate regulatory equivalence, lacks patent protection, or cannot compete with generic nilotinib pricing.
- Niche launch. The product obtains approval for a limited market based on formulation, tolerability, stability, or regional manufacturing advantages.
- Differentiated launch. The product supports a new dosage form, improved pharmacokinetics, or a clinically meaningful dosing benefit and receives stronger pricing.
The most likely base case is limited commercial value unless d-tartrate has a documented pharmaceutical advantage. Existing generic nilotinib creates a low-price benchmark and reduces the opportunity for an undifferentiated salt.
What manufacturing and geographic barriers affect the opportunity?
Manufacturing barriers could include control of salt stoichiometry, crystal form, residual solvents, particle-size distribution, impurity profiles, and scale-up reproducibility. These barriers can support process patents and trade-secret protection, but they do not replace product approval.
Geographic opportunity varies:
- The United States offers a defined FDA pathway but has strong generic competition and Orange Book litigation exposure.
- Europe may permit national or centralized applications depending on the product and legal strategy, but reference-product and data-exclusivity rules remain relevant.
- Emerging markets may offer lower development costs and faster commercial entry but generally have lower prices and weaker enforcement.
- Markets with limited generic substitution may support branded or licensed products if the salt provides a clinical or supply advantage.
Key Takeaways
- Nilotinib d-tartrate has no identified FDA-approved product or standalone commercial market.
- Tasigna contains nilotinib hydrochloride monohydrate, not nilotinib d-tartrate.[1]
- No standalone revenue, Orange Book listing, or disclosed licensing transaction has been identified for the d-tartrate form.
- The main commercial opportunity would depend on a demonstrated advantage in bioavailability, stability, dosing, manufacturing, or tolerability.
- Generic nilotinib and established CML therapies create substantial price and market-access pressure.
- Biosimilar analysis is not applicable because nilotinib is a small molecule.
- The financial profile is development-stage option value rather than an established revenue trajectory.
FAQs
Can nilotinib d-tartrate be substituted for Tasigna?
No automatic substitution should be assumed. Tasigna contains nilotinib hydrochloride monohydrate, and a d-tartrate product would require its own regulatory determination.
Is nilotinib d-tartrate covered by Tasigna patents?
Coverage cannot be presumed. Patent scope depends on claim language covering the active moiety, salt, crystal form, formulation, manufacturing process, or method of use.
Does nilotinib d-tartrate have a biosimilar pathway?
No. Biosimilar regulation applies to biological products. Nilotinib d-tartrate would be regulated as a small-molecule drug product.
Could nilotinib d-tartrate receive orphan-drug exclusivity?
Potentially, if a qualifying product and indication satisfy applicable orphan-drug requirements. No d-tartrate-specific orphan designation or exclusivity has been identified.
Is nilotinib d-tartrate commercially investable today?
It is not a revenue-generating commercial asset based on the identified evidence. Its value would depend on verified composition-of-matter or solid-form rights, regulatory feasibility, manufacturing economics, and clinical differentiation.
References
- U.S. Food and Drug Administration. (2023). Tasigna (nilotinib) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Novartis AG. (2023). Annual report 2023.
